A Phase 3 Study of Reproxalap in Subjects With Allergic Conjunctivitis
Condition: Allergic Conjunctivitis Interventions: Drug: Reproxalap Ophthalmic Solution (0.25%); Drug: Reproxalap Ophthalmic Solution (0.5%); Drug: Vehicle Ophthalmic Solution Sponsor: Aldeyra Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials